http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018369350-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d23ef94fa2c36477e4d80e9aff330caf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_538825867d57e24f31b1cc7d0c485dd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_34756853592388da4d99a130d606d440
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b91afcb74b77f7ef77c8b29e79438599
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35a6dbdca63f4ff2c4d8ad8e5422a433
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0638
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0637
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
filingDate 2016-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed137c171b3b53d6e08ede5b9c23111a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e60a05dd38d7ada6660f1760f17bf3ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_175ea221e224144e3703cfa931e2fa11
publicationDate 2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2018369350-A1
titleOfInvention Antigen-specific t cells for inducing immune tolerance
abstract Described herein are agents and methods for targeting antigen-specific B cells using engineered T cells, such as regulatory T cells or cytotoxic T cells, or bi-specific antibodies. The agents and methods can be used to reduce undesirable immune responses.
priorityDate 2015-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1134
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409525
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395454
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409524
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID187
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5789

Total number of triples: 35.